Concepedia

Author

H. Kantarjian

The University of Texas MD Anderson Cancer Center

Also Known As

H Kantarjian, H M Kantarjian, H. Kantarjian, H. M. Kantarjian, H. kantarjian, H.M. Kantarjian, Hagop Kantarjian, Hagop M Kantarjian, Hagop M. Kantarjian

233

Publications

5.6K

Citations

35

H-Index

55

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterPrincess Margaret Cancer CentreBristol-Myers Squibb (United States)Cornell UniversitySouth Australia Pathology
HK

About

H. Kantarjian is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

31

2.3K

2

Health Sciences

13

16

1.1K

3

Cell Biology

3

3

454

4

Cellular Therapies

1

1

39

5

Family Medicine

1

1

10

H. Kantarjian

×

57

Publications

4.5K

Citations

30

H-Index

YearCitations

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

MJ Keating, H. Kantarjian, Moshe Talpaz,

Blood

1989

455

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Richard A. Larson, Andreas Hochhaus, Timothy P. Hughes,

Leukemia

2012

437

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger,

Leukemia

2008

352

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Francis J. Giles, H. Kantarjian, Steve Kornblau,

Cancer

2001

280

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Michael J. Keating, H. Kantarjian, S O'Brien,

Journal of Clinical Oncology

1991

249

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian,

Haematologica

2015

245

Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.

Michael J. Keating, Terry L. Smith, H. Kantarjian,

PubMed

1988

218

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

Sima Jeha, H. Kantarjian, David Irwin,

Leukemia

2004

178

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Roland B. Walter, Megan Othus, Alan K. Burnett,

Leukemia

2014

170

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib,

Haematologica

2013

161

Page 1